High Hypoxia Inducible Factor-1α Expression and Positive Limphovascular Invasion as Risk Factors for Axillary Lymph Nodes Metastasis in Breast Cancer
Abstract
Background: Hypoxia-inducible factor-1α (HIF-1α) expression enables tumor cell proliferation and has a role in the processes of epithelial-mesenchymal transition, invasion, extravasation, and metastasis. Lymphovascular Invasion (LVI) causes a significant increase in the occurrence of axilla lymph node metastasis. This study aims to prove that high HIF-1α expression and LVI (+) as risk factors for axillary lymph node metastasis in breast cancer.
Method: The study conducted was a case-control study involving all histopathologically confirmed breast cancer patients at Prof. Dr. I.G.N.G. Ngoerah Hospital during the period from January 2019 to December 2022. In this study, the case group consisted of patients with breast cancer and axilla lymph node (+), while the control group included breast cancer patients without these characteristics. Data analysis was processed using SPSS version 26, which included descriptive statistical analysis, proportion comparison tests, and multiple logistic regression tests, with significance set at p < 0.05.
Results: LVI (+) has a risk of metastasis to lymph nodes (+) of 6 times (95% CI 1.53–23.44, P = 0.007) and adjusted OR 4.33 (95% CI 2.369–6.053; P = 0.025). The results of the HIF1-α ROC curve obtained a sensitivity value of 86.4% and specificity of 79.2% with a cut-off value of 5.4. A score ≥ 5.4 has a risk of metastasis to lymph nodes (+) of 24.01 times (95% CI 5.03–115.25; P < 0.001) and adjusted OR 24.06 (95% CI 5.026–115.247; p < 0.001).
Conclusion: High HIF-1α expression and positive lymphovascular invasion as risk factors for axillary lymph node metastasis in breast cancer, with HIF-1α showing a particularly strong association. These findings suggest their potential as predictive biomarkers for metastasis. However, the study’s retrospective, single-center design limits generalizability. Future research should validate these results in larger, multicenter cohorts and explore the underlying mechanism to enhance clinical application.
Keywords
DOI: 10.33371/ijoc.v19i2.1302
Article Metrics
Abstract View: 541, 
PDF Download: 135
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians. 2018;68:394–424.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021;71:209–49.
Lobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112:1445–51.
Chan IS, Knútsdóttir H, Ramakrishnan G, et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020;219:e202001134.
Blanco MA, Kang Y. Signaling pathways in breast cancer metastasis - novel insights from functional genomics. Breast Cancer Res. 2011;13:206.
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31–46.
Gao Y, Bado I, Wang H, et al. Metastasis Organotropism: Redefining the Congenial Soil. Dev Cell. 2019;49:375–91.
Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer. 2020;11:4474–94.
Pezzuto A, Carico E. Role of HIF-1 in Cancer Progression: Novel Insights. A Review. Curr Mol Med. 2018;18:343–51.
Zhang Y, Zhang H, Wang M, et al. Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications. Front Oncol. 2021;11:652266.
Joseph C, Alsaleem M, Orah N, et al. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat. 2020;182:267–82.
Verdial FC, Mamtani A, Pawloski KR, et al. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2022;29:3810–9.
Aryana IGPS, Adiputra PAT, Permatasari Y, et al. Breast Cancer in Older Women at Sanglah Central General Hospital. E-journal Medika Udayana. 2014;3:1–9.
Narisuari IDAPM, Manuaba IBTW. P Prevalence and characteristics of breast cancer patients in the oncology surgery polyclinic of Sanglah General Hospital, Bali, Indonesia in 2016. Medical Science Digest. 2020;11:183–9.
Aryawan ITK. Characteristics Based on Immunohistochemical Examination and Sociodemography in Breast Cancer Patients at Sanglah Central General Hospital Denpasar in 2009-2013. 2018;7:1–6.
World Health Organization. Breast Cancer. 2020; Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Ribnikar D, Ribeiro JM, Pinto D, et al. Breast cancer under age 40: a different approach. Curr Treat Options Oncol. 2015;16:16.
Kashyap D, Bal A, Irinike S, et al. Heterogeneity of the Tumor Microenvironment Across Molecular Subtypes of Breast Cancer. Appl Immunohistochem Mol Morphol. 2023;31:533–43.
Yin L, Duan JJ, Bian X-W, Yu S-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.
Yang R, Li Y, Wang H, et al. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed. 2022;3:8.
YY S, PU P. Molecular Subtypes of Invasive Breast Cancer Patients: A Systematic Review of Literature Association Of Lymphovascular Infiltration With Molecular Subtypes Of Invasive Breast Cancer: A Systematic Review. 2021;9:15–22.
Armer JM, Henggeler MH, Brooks CW, et al. The Health Deviation of Post-Breast Cancer Lymphedema: Symptom Assessment and Impact on Self-Care Agency. Self Care Depend Care Nurs. 2008;16:14–21.
Min SK, Lee SK, Woo J, et al. Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. J Breast Cancer. 2021;24:75.
Suanjaya MA, Sherliyanah S, Utami S. Prevalence and Characteristics of Breast Cancer Patients in Mataram City for the 2015-2020 Period. Jurnal Aisyah: Jurnal Ilmu Kesehatan. 2021;6.
Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170:647–56.
Ojha SS, Jain RA, Nilkanthe RG, et al. Distance of Tumor to Skin as a Predictive Marker for Axillary Lymph Node Metastasis in Cases of Breast Carcinoma - A Retrospective Study. Indian Journal of Medical and Paediatric Oncology. 2018;39:321–5.
Fujii T, Yajima R, Hirakata T, et al. Impact of the prognostic value of vascular invasion, but not lymphatic invasion, of the primary tumor in patients with breast cancer. Anticancer Res. 2014;34:1255–9.
Sidauruk JTS. H Relationship between Age and Estrogen Receptor in Breast Cancer Patients at Dr. Pirngadi Medan Hospital in 2018. Nommensen Journal of Medicine. 2020;6(1):1-4.
Firasi AA, Yudhanto E. Relationship of Age To The Degree of Difference of Breast Cancer In Women. 2016;5.
Payne SJL, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer--the present. Histopathology. 2008;52:82–90.
Thornton MJ. Estrogens and aging skin. Dermatoendocrinol. 2013;5:264–70.
Sari SE, Harahap WA, Saputra D. Effect of Risk Factors on Estrogen Receptor Expression in Breast Cancer Patients in Padang City. Andalas Health Journal. 2018;7:461.
Falk RT, Gentzschein E, Stanczyk FZ, et al. Measurement of sex steroid hormones in breast adipocytes: methods and implications. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1891-5.
Fujimoto Y, Watanabe T, Hida AI, et al. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Breast Cancer. 2019;26:738–47.
Putri NMA, Kurniati YP. Relationship Between Age and Body Mass Index (BMI) with Estrogen Receptor (ER) Molecular Phenotype in Invasive Breast Carsinoma of No Special Type (NST) Patients at PKU Muhammadiyah Surakarta Hospital[Thesis]. Universitas Muhammadiyah Surakarta. 2018;1:1–78.
Honda C, Kurozumi S, Katayama A, et al. Prognostic value of tumor‑infiltrating lymphocytes in estrogen receptor‑positive and human epidermal growth factor receptor 2‑negative breast cancer. Mol Clin Oncol. 2021;15:252.
Finn RS, Press MF, Dering J, et al. Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. JCO. 2009;27:3908–15.
Willibald M, Wurster I, Meisner C, et al. High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy. Horm Metab Res. 2017;49:595–603.
Barbano R, Copetti M, Perrone G, et al. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient’s outcome. Int J Cancer. 2011;129:536–45.
Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846–52.
Calabrò A, Beissbarth T, Kuner R, et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat. 2009;116:69–77.
dos Santos GT, Camillo ND, Berto MD, et al. Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer. Asian Pac J Cancer Prev. 2017;18:2673–8.
Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016;37:669–76.
Abubakar M, Sung H, Bcr D, et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res. 2018;20:114.
Widiana IK, Irawan H. Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pac J Cancer Care. 2020;5:281–5.
Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.
Asri A, Mayorita P, Khambri D. Relationship of Ki-67 Expression with Histopathologic Characteristics in Triple Negative Breast Cancer. Andalas Medical Magazine. 2015;38:165.
Sitompul O. The Relationship of Ki-67 Expression with Axillary Lymph Node Metastasis in Breast Cancer Patients at Haji Adam Malik Hospital Medan. University of North Sumatra Institutional Repository (RI-USU) [Internet]. 2017; Available from: https://repositori.usu.ac.id/handle/123456789/51264.
Criscitiello C, Vingiani A, Maisonneuve P, et al. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer. Breast Cancer Res Treat. 2020;183:347–54.
Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9:32.
Rojas K, Stuckey A. Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol. 2016 Dec;59(4):651-672.
Bethania KA, Rustamadji P. Association between Molecular Subtype of Invasive Breast Carcinoma with grade, lymphovascular invasion and lymph node metastasis in the Department of Anatomic Pathology FKUI/RSCM 2019. MPI. 2022;31:392–9.
Prawirohardjo AN, Soewoto W, Alfianto U. H Relationship between body mass index and grading in breast cancer. Biomedika. 2018;10.
Das S, Sen S, Mukherjee A, et al. Risk factors of breast cancer among women in eastern India: a tertiary hospital based case control study. Asian Pac J Cancer Prev. 2012;13:4979–81.
Jonjic N, Mustac E, Dekanic A, et al. Predicting sentinel lymph node metastases in infiltrating breast carcinoma with vascular invasion. Int J Surg Pathol. 2006;14:306–11.
Firdaus VRP, Asri A, Khambri D, Harahap WA. H Relationship between Histopathology Grading and Lymphovascular Infiltration with Molecular Subtypes in Invasive Breast Cancer in the Surgery Department of RSUP. Dr. M. Djamil Padang. Andalas Health Journal. 2016;5.
Haholongan DD, Ali I, Tanggo EH. Relationship of Obesity Recurrence Events in Triple Negative Breast Cancer Patients in Dr. Soetomo General Hospital Surabaya. IJPHRD. 2020;
Hermansyah D, Firsty NN. The Role of Breast Imaging in Pre- and Post-Definitive Treatment of Breast Cancer. Exon Publications. 2022;83–99.
Kim YJ, Zhao Y, Myung JK, et al. Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1α stability. Cell Rep. 2021;37:109996.
García-Fernández A, Barco I, Fraile M, et al. Factors predictive of mortality in a cohort of women surgically treated for breast cancer from 1997 to 2014. Int J Gynaecol Obstet. 2016;134:212–6.
Aleskandarany MA, Sonbul SN, Mukherjee A, Rakha EA. Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. Pathobiology. 2015;82:113–23.
Song YJ, Shin SH, Cho JS, et al. The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer. J Breast Cancer. 2011;14:198–203.
He KW, Sun JJ, Liu ZB, et al. Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers. Medicine. 2017;96:e8490.
Feig B, Ching C, Kwon D, et al. Invasive Breast Cancer. The MD Anderson Surgical Oncology Handbook. 6th ed. Texas: Lippicott William and Wilkin; 2018. p. 36.
Shea EKH, Koh VCY, Tan PH. Invasive breast cancer: Current perspectives and emerging views. Pathol Int. 2020;70:242–52.
Gurleyik G, Gurleyik E, Aker F, et al. Lymphovascular invasion, as a prognostic marker in patients with invasive breast cancer. Acta Chir Belg. 2007;107:284–7.
Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer. Ann Surg. 2004;240:306–12.
Zhang H, Wong CCL, Wei H, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012;31:1757–70.
Liu Z, Semenza GL, Zhang H. Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B. 2015;16:32–43.
Foxler DE, Bridge KS, James V, et al. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012;14:201–8.
Ren Z, Dharmaratne M, Liang H, et al. Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1α. Br J Cancer. 2024 Apr;130(6):908-924.
Collin LJ, Maliniak ML, Cronin-Fenton DP, et al. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study. Breast Cancer Res. 2021;23:103.
Maria Badowska-Kozakiewicz A, Piotr Budzik M. Triple-Negative Breast Cancer: Expression of Hypoxia-Inducible Factor 1α in Triple-Negative Breast Cancer with Metastasis to Lymph Nodes. In: Bulut N, editor. Breast Cancer and Surgery [Internet]. IntechOpen; 2018 [cited 2024 Sep 4]. Available from: https://www.intechopen.com/books/breast-cancer-and-surgery/triple-negative-breast-cancer-expression-of-hypoxia-inducible-factor-1-in-triple-negative-breast-can.
Cai FF, Xu C, Pan X, Cai L, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. Oncotarget. 2016;7:77793–x806.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
